CRISPR therapies targeting the next breakthrough in oncology
The potential of CRISPR technology has been a hot topic in the industry ever since it was first developed, but as trials progress further into […]
CRISPR
BMS puts $150M on the table in off-the-shelf cell therapy alliance with Century
Bristol Myers Squibb is partnering with Century Therapeutics, placing a $150 million bet that the biotech’s technology for engineering stem cells can produce new off-the-shelf […]
Bayer trumpets $1bn CRISPR deal with Mammoth Bio
Bayer has bolstered its cell and gene therapy platform by securing access to a CRISPR-based gene-editing platform developed by US biotech Mammoth Biosciences. The German […]
Sana Entered into an Agreement with Beam for Non-Exclusive Commercial Rights of its CRISPR Cas12b Nuclease System for Cell Therapy Programs
Shots: Beam to receive $50M up front & is eligible to receive a target option exercise fees, milestones upon achievement of development & sales milestones […]
Aiming for better genetic medicines delivery, startup GenEdit grabs $26M
Biotech startup GenEdit is developing polymer nanoparticle technology to deliver genetic medicines, an approach intended to avoid the limitations of viral vectors. Already partnered with […]
Mammoth Bio’s massive $195M financing makes the CRISPR company a unicorn
Mammoth Biosciences is applying CRISPR technology to both diagnostics and therapeutics. With the new financing, CEO Trevor Martin said that the company is looking ahead […]
CRISPR biotech Caribou Biosciences’ IPO reels in $304M for next-gen cell therapy
Caribou Biosciences’ CRISPR approach to cell therapy sparked strong investor interest, enabling the clinical-stage biotech to upsize its IPO and raise $304 million in the […]
Pharma’s use of synthetic biology could deliver radical innovation
Synthetic biology holds much promise for the life sciences sector as it continues to look for new ways of treating disease and accelerating drug development, […]
Pharma’s use of synthetic biology could deliver radical innovation
Synthetic biology holds much promise for the life sciences sector as it continues to look for new ways of treating disease and accelerating drug development, […]
Nobel winner Charpentier’s CRISPR Therapeutics gets $900m in reworked Vertex deal
CRISPR Therapeutics is to receive a hefty $900m payment from Vertex after the companies amended a collaboration to develop, manufacture and market a gene editing […]
Casting aside CRISPR scissors and making a point with base editors
Dr Jennifer Harbottle, senior scientist in the R&D Base Editing team of PerkinElmer’s Horizon Discovery business, looks at progress made in the realms of biotechnology […]
Gene editing: beyond the hype
Genome editing is an exciting but still nascent field, and companies in the area face as many obstacles as they do opportunities. Sangamo CEO Sandy […]
2nd RNA Editing Summit 2020
Visit our website: www.rna-editing-summit.com The only industry-led meeting showcasing the recent development of RNA editing mechanisms and dedicated to realizing the research and therapeutics opportunity […]
